www.finanzen.net/analyse/Verastem_Buy-BTIG_Research_648347
|
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
U.S. Commercial Launch of COPIKTRA™ Underway
$1.7 Million in 2018 Net Product Revenues from COPIKTRA
Cash, Cash Equivalents and Short-Term Investments of $249.7 million as December 31, 2018
http://services.corporate-ir.net/SEC.Enhanced/...749&fid=16139311
Verastem meldet Zahlen für 2018
investor.verastem.com/...amp;p=irol-newsArticle&ID=2391045
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 251 | Verastem - Turnaroundspekulation 2016 | Balu4u | Vassago | 19.01.24 13:08 | |
3 | wieso "wieder" ? Zweistelligkeit war nie gegeben! | bauwi | grips | 01.03.20 17:06 |